Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
McGill University
$105,000.00
Roles of PTP1B in prostate cancer
EF 2010-11
Résumé
Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer related death in North American men. An important correlation exists between increased obesity and increased risk of developing prostate cancer. This project will utilize cutting edge research technology to examine the function that a protein named
PTP1B plays in prostate cancer. Identified as a target for new anti-diabetic drugs, in collaboration with other members of the laboratory, our preliminary results suggest that increased PTP1B is associated with an increase in initiation and progression of prostate cancer. As these new anti-PTP1B drugs will shortly enter the market for metabolic diseases such as type II diabetes and obesity, it is critical to better understand the consequence of inhibiting PTP1B in prostate cancer. By combining both cellular and animal based approaches, we will identify new cellular markers and targets that
can be exploited for both screening and potential treatment options in prostate cancer. My objective is to provide all the validation and crucial information required to rapidly move anti-PTP inhibitors to the prostate cancer clinic. To complete this goal I am also generating a novel prostate cancer mouse model, which will be used to study disease progression and efficacy of PTP1B inhibitors in a preclinical setting. This project is at the forefront of identifying novel prostate cancer markers that can serve as new targets for prostate cancer therapy.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
229588
Name
Feldhammer Matthew
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Roles of PTP1B in prostate cancer
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Animal Models; Biochemistry; Biomarkers; Mass Spectrometry; Prostate Cancer; Proteomics; Signal Transduction; Substrate Identification; Transgenics; Tyrosine Phosphatases
Abstract
Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer related death in North American men. An important correlation exists between increased obesity and increased risk of developing prostate cancer. This project will utilize cutting edge research technology to examine the function that a protein named
PTP1B plays in prostate cancer. Identified as a target for new anti-diabetic drugs, in collaboration with other members of the laboratory, our preliminary results suggest that increased PTP1B is associated with an increase in initiation and progression of prostate cancer. As these new anti-PTP1B drugs will shortly enter the market for metabolic diseases such as type II diabetes and obesity, it is critical to better understand the consequence of inhibiting PTP1B in prostate cancer. By combining both cellular and animal based approaches, we will identify new cellular markers and targets that
can be exploited for both screening and potential treatment options in prostate cancer. My objective is to provide all the validation and crucial information required to rapidly move anti-PTP inhibitors to the prostate cancer clinic. To complete this goal I am also generating a novel prostate cancer mouse model, which will be used to study disease progression and efficacy of PTP1B inhibitors in a preclinical setting. This project is at the forefront of identifying novel prostate cancer markers that can serve as new targets for prostate cancer therapy.
Competitiondate
201010
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Feldhammer, Matthew
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~